Journal
TOXINS
Volume 14, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/toxins14120844
Keywords
botulinum neurotoxin; laryngeal dystonia; spasmodic dysphonia; injection; electromyography
Categories
Ask authors/readers for more resources
Laryngeal dystonia is a chronic disorder affecting laryngeal movement, primarily interfering with phonation and speech, significantly diminishing patients' quality of life. Botulinum neurotoxin is the standard treatment for LD, with this article providing a comprehensive overview of its clinical application and therapeutic injection techniques in managing LD.
Laryngeal dystonia (LD), or spasmodic dysphonia (SD), is a chronic, task-specific, focal movement disorder affecting the larynx. It interferes primarily with the essential functions of phonation and speech. LD affects patients' ability to communicate effectively and significantly diminishes their quality of life. Botulinum neurotoxin was first used as a therapeutic agent in the treatment of LD four decades ago and remains the standard of care for the treatment of LD. This article provides an overview of the clinical application of botulinum neurotoxin in the management of LD, focusing on the classification for this disorder, its pathophysiology, clinical assessment and diagnosis, the role of laryngeal electromyography and a summary of therapeutic injection techniques, including a comprehensive description of various procedural approaches, recommendations for injection sites and dosage considerations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available